Form 4: Acelyrin Inc. Executive Melanie Gloria Reports Stock Option Grant

Melanie Gloria, Chief Operating Officer of Acelyrin, Inc., reports the acquisition of stock options.

Summary

• Melanie Gloria, the Chief Operating Officer of Acelyrin, Inc. (SLRN), reported a transaction on May 23, 2024.
• She acquired employee stock options, granting her the right to buy 184,042 shares of common stock at an exercise price of $4.22.
• The options vest in three tranches: 33% on December 15, 2024, 34% on June 15, 2025, and the remaining 33% on December 15, 2025, contingent upon continued service.
• The options expire on May 22, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future. The sentiment is neutral to positive.

Positives

• The grant of stock options aligns the COO's interests with those of the shareholders, incentivizing her to contribute to the company's success.
• The vesting schedule encourages continued service and commitment from the COO.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options to incentivize their executives.
• The vesting schedule and exercise price are typical for such grants, designed to reward long-term performance and retention.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns management's interests with the company's long-term success.
• Employees may see the grant as a sign of the company's commitment to its leadership team.

Key Dates